title: CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation.
abstract: OBJECTIVE
  Defining the reliability of cancer antigen-125-related kinetics criteria versus Gynecologic Cancer Inter Group criteria in predicting the tumor outcome after chemotherapy in patients with recurrent ovarian cancer.
  
  
  METHODS
  A retrospective monoinstitutional assessment of CA125-related versus Gynecologic Cancer Inter Group-related parameters was performed after cytotoxic chemotherapy in patients with metastatic ovarian cancer treated from 2006 to 2011. A correlation analysis between the response and progression measurements has been performed, and the outcome has been reported.
  
  
  RESULTS
  Among 42 eligible patients, tumor response and progression calculated by CA125 kinetics, with tumor response at 8 weeks and specific growth rate at progression, exhibited a significant correlation with progression-free and overall survival, similar to tumor response and progression by Gynecologic Cancer Inter Group criteria.
  
  
  CONCLUSIONS
  The tumor response at 8 weeks higher than 1.77 appears to be a good surrogate of clinical response, whereas the definition of progression when CA125 increases above a value double than the nadir suggests a similar performance of growth rate at progression versus Gynecologic Cancer Inter Group criteria and warrants further investigation.
authors.affiliation: *Division of Medical Oncology, 'G. Borea' Hospital, Via G. Borea, 56 - I-18038, Sanremo (Imperia), Italy. g.colloca@katamail.com.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Colloca
authors.forename: Antonella
authors.initials: A
authors.lastname: Venturino
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Addamo
authors.forename: Zaira
authors.initials: Z
authors.lastname: Coccorullo
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ratti
authors.forename: Graziano
authors.initials: G
authors.lastname: Caltabiano
authors.forename: Domenico
authors.initials: D
authors.lastname: Guarneri
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018394:CA-125 Antigen / Q000378:metabolism*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007700:Kinetics; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins
keywords: Ovarian cancer; chemotherapy; surrogate end point; tumor growth rate